Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Reviews in Allergy & Immunology
Published in: Clinical Reviews in Allergy & Immunology 2-3/2009

01-06-2009

Microthrombotic/Microangiopathic Manifestations of the Antiphospholipid Syndrome

Authors: Sonja Praprotnik, Dušan Ferluga, Alenka Vizjak, Anastazija Hvala, Tadej Avčin, Blaž Rozman

Published in: Clinical Reviews in Allergy & Immunology | Issue 2-3/2009

Login to get access

Abstract

The paper presents an overview of clinical manifestations and histopathologic findings in different organs in microvascular thrombotic and microangiopathic antiphospholipid syndrome (MAPS). Subsets of antiphospholipid syndrome (APS) are presented and defined. Clinico-pathologic correlations seem insufficient so far, because of a lack of detailed systematic studies of the histopathology in different organs. Based on their own autopsy and biopsy studies, the authors propose a novel categorization of histopathologic lesions that occur in patients with classic and catastrophic APS. In addition to the already accepted category of a microvascular thrombotic type of lesions, microangiopathic lesions consistent with thrombotic microangiopathy are proposed to be included in new revised classification criteria for definite APS. Microvascular thrombotic and so far underestimated microangiopathic histopathologic lesions have been shown to appear in various combinations and of different ages in patients with both classic and catastrophic APS, which fits into the concept of MAPS. These preliminary findings of our studies are also in line with the most recent hypothesis of two main mechanisms in the pathogenesis of APS, emphasizing a key role of endothelial cell affection induced by aPL on the one hand and interference with coagulation cascade on the other side.
Literature
1.
Hughes G, Harris EN, Gharavi A (1986) The anticardiolipin syndrome. J Rheumatol 13:486–489PubMed
2.
3.
Asherson RA (1992) The catastrophic antiphospholipid syndrome. J Rheumatol 19:508–512PubMed
4.
Lie JT (1997) Prevalence and pathology of vascular occlusive disease in the antiphospholipid syndrome. Cardiovasc Pathol 6:185–195CrossRef
5.
Asherson RA, Cervera R, Piette JC et al (1998) Catastrophic antiphospholipid syndrome. Clinical and laboratory features in 50 patients. Medicine 80:195–207CrossRef
6.
Wilson WA, Gharavi AE, Koike T et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 42:1309–1311PubMedCrossRef
7.
8.
Baker WF, Bick RL (2008) The clinical spectrum of antiphospholipid syndrome. Hematol Oncol Clin North Am 22:33–52PubMedCrossRef
9.
Montero PJ, Franco V, Strauss Y, La Pena A (2008) The antiphospholipid syndrome. Medicrit 5:27–40
10.
Vora SK, Asherson RA, Erkan D (2006) Catastrophic antiphospholipid syndrome. J Intens Care Med 21:144–159CrossRef
11.
Miyakis S, Lochshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306PubMedCrossRef
12.
Asherson RA (2006) New subsets of the antiphospholipid syndrome in 2006: “PRE-APS” (probable APS) and microangiopathic antiphospholipid syndrome (“MAPS”). Autoimmun Rev 6:76–80PubMedCrossRef
13.
Asherson RA, Cervera R (2008) Microvascular and microangiopathic antiphospholipid associated syndromes (“MAPS”): Semantic or antisemantic. Autoimmun Rev 7:164–167PubMedCrossRef
14.
Espinosa G, Buciarelli S, Cervera R (2004) Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis 63:730–736PubMedCrossRef
15.
Reyes E, Alarcon-Segovia D (2002) Pathology of the antiphospholipid syndrome. In: Asherson RA et al (ed) The Antiphospholipid Syndrome II: Autoimmune Thrombosis. Elsevier, Amsterdam, pp 131–136
16.
Cervera R, Piette JC, Font J et al (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019–1027PubMedCrossRef
17.
Nahass GT (1997) Antiphospholipid antibodies and the antiphospholipid antibodies syndrome. J Am Acad Dematol 36:149–168CrossRef
18.
Alegre VA, Winkelmann RK (1988) Histopathologic and immunofluorescence study of skin lesions associated with circulating anticoagulant. J Am Acad Dermatol 19:117–124PubMedCrossRef
19.
Smith KJ, Skelton HG, James WD et al (1990) Cutaneous histopathologic findings in “antiphospholipid syndrome”. Arch Dermatol 126:1176–1183PubMedCrossRef
20.
Stephansson EA, Niemi KM, Jouhikainen T et al (1991) Lupus anticoagulant and the skin. A long term follow-up of SLE patients with special reference to histopathologic findings. Acta Derm Venereol 71:416–422PubMed
21.
Grob JJ, Bonerandi JJ (1986) Cutaneous manifestations associated with the presence of the lupus anticoagulant: a report of two cases and the review of the literature. J Am Acad Dermatol 15:211–219PubMedCrossRef
22.
Selva A, Ordi J, Roca M et al (1994) Pyoderma gangrenosum-like ulcers associated with lupus anticoagulant. Dermatology 189:182–184PubMedCrossRef
23.
Hughson MD, McCarty GA, Brumback RA (1995) Spectrum of vascular pathology affecting patients with the antiphospholipid syndrome. Hum Pathol 26:716–724PubMedCrossRef
24.
Lie JT (1994) Vasculitis in the antiphospholipid syndrome: culpit or consort. J Rheumatol 21:397–399PubMed
25.
Mujic F, Lloyd M, Cuadrado MJ et al (1995) Prevalence and clinical significance of subungual splinter hemorrhages in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 13:327–331PubMed
26.
Ornstein MH, Rand JH (1994) An association between refractory HELLP syndrome and antiphospholipid antibodies during pregnancy; a report of 2 cases. J Rheumatol 21:1360–1364PubMed
27.
Frances C, Piette CP (2002) Dermatologic manifestations in the antiphospholipid syndrome. In: Asherson RA et al (ed) The Antiphospholipid Syndrome II: Autoimmune Thrombosis. Elsevier, Amsterdam, pp 235–244
28.
Frances C, Piette JC, Asherson RA (2006) Dermatologic aspects of antiphospholipid antibody syndrome. In: Sarzi-Puttini P et al (eds) Handbook of Systemic Autoimmune Diseases. Elsevier 5:103–117
29.
Frances C, Niang S, Laffitte E et al (2005) Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis Rheum 52:1785–1793PubMedCrossRef
30.
Šipek-Dolničar A, Hojnik M, Božič B et al (2002) Clinical presentations and vascular histopathology in autopsied patients with systemic lupus erythematosus and anticardiolipin antibodies. Clin Exp Rheumatol 20:335–342PubMed
31.
Creamer D, Black MM, Calonje E (2000) Reactive angioendotheliomatosis in association with the antiphospholipid syndrome. J Am Acad Dermatol 42:903–906PubMedCrossRef
32.
Thai KE, Barrett W, Kossard S (2003) Reactive angioendotheliomathosis in the setting of antiphospholipid syndrome. Australas J Dermatol 14:99–106
33.
Sharkey MP, Daryanani II, Gillett MB, Jones SK (2002) Localized cutaneous necrosis associated with the antiphospholipid syndrome. Australas J Dermatol 43:218–220PubMedCrossRef
34.
Tomb R, Maalouf E, Attoui S (2008) Cutaneous nodular lesions and antiphospholipid syndrome. Ann Dermatol Venereol 135:484–487PubMedCrossRef
35.
Bucciarelli S, Cervera R, Espinosa G et al (2006) Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors. Autoimmun Rev 6:72–75PubMedCrossRef
36.
Maggiorini M, Knoblauch A, Schneider J, Russi EW (1997) Diffuse microvascular pulmonary thrombosis associated with primary antiphospholipid antibody syndrome. Eur Respir J 10:727–730PubMed
37.
Kerr JE, Poe J, Kramer Z (1997) Antiphospholipid antibody syndrome presenting as a refractory noninflammatory pulmonary vasculopathy. Chest 112:1707–1710PubMedCrossRef
38.
Deane KD, West SG (2005) Antiphospholipid antibodies as a cause of pulmonary capillaritis and diffuse alveolar hemorrhage: a case series and literature review. Semin Arthritis Rheum 35:154–165PubMedCrossRef
39.
Espinosa G, Cervera R, Garcia-Carrasco et al (2002) Pulmonary involvement in the antiphospholipid syndrome. In: Wells AU, Denton CP (eds) Handbook of Systemic Autoimmune Disease. Amsterdam, Elsevier 2:137–145
40.
Šipek-Dolničar A, Hojnik M, Rozman B et al (2000) Small vessel thrombosis without major thrombotic events in systemic lupus erythematosus patients with antiphospholipid syndrome. Wien Klin Wochenschr 112:707–710PubMed
41.
Long BR, Leya F (2008) The role of antiphospholipid syndrome in cardiovascular disease. Hematol Oncol Clin North Am 22:79–94PubMedCrossRef
42.
Leung WH, Wong KL, Lau et al (1990) Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med 89:411–419
43.
Murphy J, Leach IH (1989) Findings at necropsy in the heart of a patient with anticardiolipin syndrome. Br Heart J 62:61–64PubMedCrossRef
44.
Brown JH, Doherty CC, Allen DC et al (1988) Fatal cardiac failure due to myocardial microthrombi in systemic lupus erythematosus. Br Med J (Clin Res Ed) 296:1505CrossRef
45.
Kaplan SD, Chartash EK, Pizzarello RA et al (1992) Cardiac manifestations of the antiphospholipid syndrome. Am Heart J 124:1331–1338PubMedCrossRef
46.
Von Landenberg P, Asherson RA, Piette JC (2002) Renal, hepatic and other intraabdominal manifestations in the antiphospholipid syndrome. In: Asherson et al (ed) The Antiphospholipid Syndrome II: Autoimmune Thrombosis. Elsevier, Amsterdam, pp 189–204
47.
Uthman I, Khamashta M (2007) The abdominal manifestation of the antiphospholipid syndrome. Rhematol 46:1641–1647CrossRef
48.
Nakamura H, Uchara H, Okada T (1989) Occlusion of small hepatic veins associated with systemic lupus erythematosus with the lupus anticoagulant and anti-cardiolipin antibody. Hepatogastroenterol 36:393–397
49.
Barak N, Orion Y, Schneider M et al (1999) Case report: hepatic involvement in antiphospholipid syndrome. J Gastroenterol Hepatol 14:1124–1128PubMedCrossRef
50.
Kalman DR, Khan A, Romain PL, Nompleggi DJ (1996) Giant gastric ulceration associated with antiphospholipid antibody syndrome. Am J Gastroenterol 91:1244–1247PubMed
51.
Briley DP, Coull BM, Goodnight SH (1989) Neurological disease associated with antiphospholipid syndrome. Ann Neurol 25:221–227PubMedCrossRef
52.
Asherson RA, Cervera R (2003) The antiphospholipid syndrome: multiple faces beyond the classical presentation. Autoimmun Rev 2:140–151PubMedCrossRef
53.
Cuadrado MJ, Khamashta MA, Ballesteros A et al (2000) Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine 79:57–68PubMedCrossRef
54.
Tektonidou MG, Grigorios Kotoulas NV, Antoniou A, Moutsopoulos HM (2006) Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch Intern Med 166:2278–2284PubMedCrossRef
55.
Brey RL, Levine SR, Stallworth CL (2002) Neurologic manifestations in the antiphospholipid syndrome. In: Asherson RA et al (ed) The Antiphospholipid Syndrome II: Autoimmune Thrombosis. Elsevier, Amsterdam, pp 155–168
56.
Shoenfeld Y, Nahum A, Korczyn AD et al (2003) Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus 12:436–442PubMedCrossRef
57.
Hugson MD, McCarty GA, Sholer CM, Brumback RA (1993) Thrombotic cerebral arteriopathy in patients with the antiphospholipid syndrome. Mod Pathol 6:644–653
58.
Miesbach W, Gilzinger A, Gokpinar B et al (2006) Prevalence of antiphospholipid antibodies in patients with neurological symptoms. Clin Neurol Neurosur 108:135–142CrossRef
59.
Durrani OM, Gordon C, Murray PI (2002) Primary anti-phospholipid antibody syndrome (APS). Surv Ophthalmol 4:215–238CrossRef
60.
Asherson RA, Merry P, Acheson JF et al (1989) Antiphospholipid antibodies: a risk factor for occlusive ocular vascular disease in systemic lupus erythematosus and the primary antiphospholipid syndrome. Ann Rheum Dis 48:358–361PubMedCrossRef
61.
Castanon C, Amigo MC, Banales JL et al (1995) Ocular vaso-occlusive disease in primary antiphospholipid syndrome. Ophthalmology 102:256–262PubMed
62.
Giorgi D, Pace F, Giorgi A et al (1999) Retinopathy in systemic lupus erythematosus: pathogenesis and approach to therapy. Hum Immunol 60:688–696PubMedCrossRef
63.
Falcini F, Taccetti G, Ermini M et al (1997) Catastrophic antiphospholipid antibody syndrome in pediatric systemic lupus erythematosus. J Rheumatol 24:389–392PubMed
64.
Asherson RA, Cervera R, Piette JC et al (2001) Catastrophic antiphospholipid syndrome. Clues to the pathogenesis from a series of 80 patients. Medicine 80:355–377PubMedCrossRef
65.
Tsirpanlis G, Moustakas G, Sakka E et al (2005) Catastrophic antiphospholipid syndrome in a 14-year-old child. Pediatr Nephrol 20:519–521PubMedCrossRef
66.
Avčin T, Cimaz R, Silverman ED et al (2008) Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics 122:1100–1107CrossRef
67.
Orsino A, Schneider R, DeVeber G et al (2004) Childhood acute myelomonocytic leukemia (AML-M4) presenting as catastrophic antiphospholipid antibody syndrome. J Pediatr Hematol Oncol 26:327–330PubMedCrossRef
68.
Sharma J, Karthik S, Rao S et al (2005) Catastrophic antiphospholipid antibody syndrome. Pediatr Nephrol 20:998–999PubMedCrossRef
69.
Park JM, Shin JI, Shin YH et al (2007) Catastrophic antiphospholipid syndrome in a 7-year-old girl. Clin Rheumatol 26:1011–1013PubMedCrossRef
70.
Iman S, Sidki K, al-Marshedy AR, Judzewitsch R (1991) Addison’s disease, hypertension, renal and hepatic microthrombosis in ‘primary’ antiphospholipid syndrome. Postgrad Med J 67:385–388CrossRef
71.
De-Leon-Bojorge B, Zaltzman-Girsevich S, Ortega-Salgado A et al (2006) Thrombotic microangiopathy involving the gallbladder as an unusual manifestation of systemic lupus erythematosus and antiphospholipid syndrome: case report and review of the literature. World J Gastroenterol 12:7206–7209PubMed
72.
Do Sameiro Faria M, Mota C, Barlot J et al (2000) Hemolytic uremic syndrome cardiomyopathy, cutaneous vasculopathy and antiphospholipid activity. Nephrol Dial Transplant 15:1891–1892PubMedCrossRef
73.
Meglič A, Grosek Š, Benedik-Dolničar M, Avčin T (2008) Atypical haemolytic uremic syndrome complicated by microangiopathic antiphospholipid-associated syndrome. Lupus 17:842–845PubMedCrossRef
74.
Symmers WSC (1952) Thrombotic microangiopathic haemolitic anemia (thrombotic microangiopathy). Br Med J 2:897–903PubMed
75.
Thoenes W, John HD (1980) Endotheliotropic (hemolytic) nephroangiopathy and its various manifestation forms (thrombotic microangiopathy, primary malignant nephrosclerosis, hemolytic–uremic syndrome). Klin Wochenschr 58:173–184PubMedCrossRef
76.
Asherson RA, Cervera R, Merrill JT (2006) Thrombotic microangiopathic antiphospholipid syndromes: a continuum of conditions. Future Rheumatol 1:355–364CrossRef
77.
Asherson RA, Pierangeli S, Cervera R (2007) Is there a microangiopathic antiphospholipid syndrome. Ann Rheum Dis 66:429–432PubMedCrossRef
78.
Vega-Ostertag ME, Pierangeli SS (2007) Mechanisms of aPL-mediated thrombosis: effects of aPL on endothelium and platelets. Curr Rheumatol Rep 9:190–197PubMedCrossRef
79.
80.
Mackworth-Young CG (2004) Antiphospholipid syndrome: multiple mechanisms. Clin Exp Immunol 136:393–401PubMedCrossRef
81.
D’Agati V, Kunis C, Williams G, Appel GB (1990) Anti-cardiolipin antibody and renal disease: a report of three cases. J Am Soc Nephrol 1:777–784PubMed
82.
Nochy D, Daugas E, Droz D et al (1999) The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol 10:507–518PubMed
83.
Amigo MC, Garcia-Torres R (2000) Kidney disease in antiphospholipid syndrome. In: Khamashta MA (ed) Hughes Syndrome. Antiphopholipid Syndrome. Springer, Berlin, pp 71–81
84.
Seshan SV (2000) Vascular complications in lupus nephritis and lupus-like syndromes. Wien Klin Wochenschr 112:687–691PubMed
85.
Daugas E, Nochy D, Le Thi Huong D et al (2002) Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol 13:42–52PubMedCrossRef
86.
87.
Hill GS, Nochy D (2007) Antiphospholipid syndrome in systemic lupus erythematosus. J Am Soc Nephrol 18:2461–2464PubMedCrossRef
88.
Jara LJ, Medina G, Vera-Lastra O (2007) Systemic antiphospholipid syndrome and atherosclerosis. Clin Rev Allerg Immunol 32:172–177CrossRef
89.
Moroni G, Ventura D, Riva P et al (2004) Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 43:28–36PubMedCrossRef
90.
Fakhouri F, Noël LH, Zuber J et al (2003) The expanding spectrum of renal diseases associated with antiphospholipid syndrome. Am J Kidney Dis 41:1205–1211PubMedCrossRef
91.
Asherson RA, Espinosa G, Cervera R et al (2005) Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients. Ann Rheum Dis 64:943–946PubMedCrossRef
92.
Voung PN, Berry SC (2002) The Pathology of Vessels. Springer, Berlin, pp 35–67
93.
Bontas E, Tanikawa A, Bartos D et al (2006) Polymorphism of skin involvement in Hughes (antiphospholipid) syndrome. J Thromb Haemost 4:295–306CrossRef
94.
Rollino C, Mazzucco G, Boero R (2003) Is it possible to diagnose primary anti-phospholipid syndrome (PAPS) on the basis of renal thrombotic microangiopathy (PAPS nephropathy) in the absence of other thrombotic process. Renal Failure 25:1043–1049PubMedCrossRef
95.
Saracino A, Ramuni A, Pannarale G, Coratelli P (2005) Kidney disease associated with primary antiphospholipid syndrome: clinical signs and histopathologic features in an case experience of five cases. Clin Nephrol 63:471–476PubMed
96.
Griffiths MH, Papadaki L, Neild GH (2000) The renal pathology of primary antiphospholipid syndrome: a distinctive form of endothelial injury. Q J Med 93:457–467
97.
Tektonidou MG, Sotsiou F, Nakopoulou L et al (2004) Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies. Arthritis Rheum 50:2569–2579PubMedCrossRef
98.
Asherson RA, Cervera R, Shepshelovich D, Shoenfeld Y (2006) Nonthrombotic manifestations of the antiphospholipid syndrome: away from thrombosis. J Rheumatol 33:1038–1344PubMed
99.
Pilling J, Cutaia M (1997) The antiphospholipid antibody syndrome: a vascular disease with pulmonary manifestations. Chest 112:1451–1453PubMedCrossRef
100.
Johnson CM, Mureebe L, Silver D (2005) Hypercoagulable states: a review. Vasc Endovasc Surg 39:123–133CrossRef
101.
102.
Matsuura E, Kobayashi K, Lopez LR (2008) Preventing autoimmune and infection triggered atherosclerosis for an enduring healthful lifestyle. Autoimmun Rev 7:214–222PubMedCrossRef
103.
Yang YH, Chuang YH, Wang LC et al (2008) The immunobiology of Henoch–Schonlein purpura. Autoimmun Rev 7:179–184PubMedCrossRef
104.
105.
Belizna CC, Richard V, Thuillez C et al (2007) Insights into atherosclerosis therapy in antiphospholipid syndrome. Autoimmun Rev 7:46–51PubMedCrossRef
106.
Rav-Acha M, Plot L, Peled N, Amital H (2007) Coronary involvement in Takayasu’s arteritis. Autoimmun Rev 6:566–71PubMedCrossRef
107.
Alard JE, Dueymes M, Youinou P, Jamin C (2007) Modulation of endothelial cell damages by anti-Hsp60 autoantibodies in systemic autoimmune diseases. Autoimmun Rev 6:438–43PubMedCrossRef
108.
Hahn BH, Grossman J, Chen W, McMahon M (2007) The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 28:69–75PubMedCrossRef
109.
110.
Koike T, Bohgaki M, Amengual O, Atsumi T (2007) Antiphospholipid antibodies: lessons from the bench. J Autoimmun 28:129–33PubMedCrossRef
Metadata
Title
Microthrombotic/Microangiopathic Manifestations of the Antiphospholipid Syndrome
Authors
Sonja Praprotnik
Dušan Ferluga
Alenka Vizjak
Anastazija Hvala
Tadej Avčin
Blaž Rozman
Publication date
01-06-2009
Publisher
Humana Press Inc
Published in
Clinical Reviews in Allergy & Immunology / Issue 2-3/2009
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-008-8104-z

Other articles of this Issue 2-3/2009

Clinical Reviews in Allergy & Immunology 2-3/2009 Go to the issue

OriginalPaper

Renal Involvement in the Antiphospholipid Syndrome (APS)—APS Nephropathy

OriginalPaper

The Role of Complement in the Antiphospholipid Syndrome-Associated Pathology

OriginalPaper

Catastrophic Antiphospholipid Syndrome: Treatment, Prognosis, and the Risk of Relapse

OriginalPaper

Plasma Homocysteine Levels, The Prevalence of Methylenetetrahydrofolate Reductase Gene C677T Polymorphism and Macrovascular Disorders in Systemic Sclerosis: Risk Factors for Accelerated Macrovascular Damage?

OriginalPaper

Recent Advances in the Treatment of Systemic Sclerosis

OriginalPaper

Ronald A. Asherson—“In Memoriam”
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits